Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics
筆頭著者：Schüttler J
雑誌：Anesthesiology. 2020; 132(4): 636-651.
分類：全身麻酔
お客様の環境により、メールで申し込み＞をクリックしてもメール
ソフトが立ちあがらないことがございます。その場合は下記項目を
inquiry@mundipharma.co.jp 宛にお送りください。
担当者より順次ご連絡いたします。
①ご希望の文献タイトル、②著者、③文献送付先、④ご所属、⑤お名前
Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part II. Pharmacodynamics of Electroencephalogram Effects
筆頭著者：Eisenried A
雑誌：Anesthesiology. 2020; 132(4): 652-666.
分類：全身麻酔
Post-induction hypotension with remimazolam versus propofol in patients routinely administered angiotensin axis blockades: a randomized control trial
筆頭著者：Song SW
雑誌：BMC Anesthesiol. 2023; 23(1): 219.
分類：全身麻酔
Effects of Remimazolam vs. Sevoflurane Anesthesia on Intraoperative Hemodynamics in Patients with Gastric Cancer Undergoing Robotic Gastrectomy: A Propensity Score-Matched Analysis
筆頭著者：Lee B
雑誌：J Clin Med. 2022; 11(9): 2643.
分類：全身麻酔
Quality of recovery in patients administered remimazolam versus those administered an inhalant agent for the maintenance of general anesthesia: a randomized control trial
筆頭著者：Song SW
雑誌：BMC Anesthesiol. 2022; 22(1): 226.
分類：全身麻酔
Re-sleeping after reversal of remimazolam by flumazenil
筆頭著者：Yamamoto T
雑誌：J Anesth. 2021; 35(2): 322.
分類：全身麻酔
Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia
筆頭著者：Dai G
雑誌：Minerva Anestesiol. 2021; 87(10): 1073-1079.
分類：全身麻酔
The use of remimazolam versus propofol for induction and maintenance of general anesthesia: A systematic review and meta-analysis
筆頭著者：Ko CC
雑誌：Front Pharmacol. 2023; 14: 1101728.
分類：全身麻酔
Remimazolam Anesthesia for MitraClip Implantation in a Patient with Advanced Heart Failure
筆頭著者：Satoh T
雑誌：Case Rep Anesthesiol. 2021; 2021: 5536442.
分類：全身麻酔
Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma atient with a history of autologous stem cell transplantation:Case report of a patient followed over 3 years under pralatrexate treatment
著者：Alparslan Merdin et al
雑誌：Medicine(Baltimore) vol98(30), 2019 Jul
病型：PTCL-NOS
Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients
著者：Ning-Chun Chen et al
誌名：Journal of the Formosan Medical Association Available online 7 August 2023
病型：PTCL-NOS
Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma
著者：Owen A O'Connor 1, Bor-Sheng Ko 2 3, Ming-Chung Wang 4, Dai Maruyama 5 6, Yuqin Song 7, Ee-Min Yeoh 8, Nick Manamley 9, Kensei Tobinai 5
誌名：blood advances. 2024 June 11;8(11):2601-2611.
Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report
著者：Yao-Chung Liu
雑誌：J Med Case Rep. 2020 Mar 17;14(1):43.
病型：ENKL-nasal type
Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
著者：Yasunobu Sekiguchi
雑誌：J Clin Exp Hematop. 2020;60(1):26-28.
病型：PTCL-NOS
Leucovorin Administration Allows Continued Pralatrexate Treatment in a Patient with Angioimmunoblastic T-Cell Lymphoma
著者：Koichi Sawada
雑誌：癌と化学療法
病型：AITL
A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature
著者：Helen Ma
雑誌：Leuk Lymphoma. 2019 Dec;60(13):3300-3303.
Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma
著者：Shin Yeu Ong
雑誌：Ann Acad Med Singap. 2019 Sep;48(9):298-300.
病型：SPTCL
Successful treatment of monomorphic epitheliotropic intestinal T cell lymphoma with pralatrexate
著者：Rie Tabata
雑誌：Ann Hematol. 2019 May;98(5):1301-1303.
病型：EATL
Misdiagnosed Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type, Successfully Treated: A Case Report
著者：José Domingo Saavedra Ramírez
雑誌：Case Rep Oncol. 2017 Oct 26;10(3):948-953.
病型：ENKL-nasal type
Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey
著者：Mehmet Sinan Dal
雑誌：J BUON. 2021 Jul-Aug;26(4):1536-1539.
Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis
著者：Jun Zhu
雑誌：Leuk Lymphoma. 2020 Sep;61(9):2145-2152.
病型：AITL
Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
著者：Xiaonan Hong
雑誌：Target Oncol. 2019 Apr;14(2):149-158.
Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study
著者：Owen A O'Connor
雑誌：JNCI Cancer Spectr. 2018 Dec 1;2(4):pky038.
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma
著者：Dai Chihara
雑誌：Br J Haematol. 2017 Mar;176(5):750-758.
雑誌：PTCL-NOS、AITL
お客様の環境により、メールで申し込み＞をクリックしてもメール
ソフトが立ちあがらないことがございます。その場合は下記項目を
inquiry@mundipharma.co.jp 宛にお送りください。
担当者より順次ご連絡いたします。
①ご希望の文献タイトル、②著者、③文献送付先、④ご所属、⑤お名前
Ⓡ:アネレムはムンディファーマの登録商標です。